Unlocking the power of the immune system against cancer and autoimmune disease.

A Global Leader in LAG-3 Immunotherapy for Cancer and Autoimmune Diseases

Immutep is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.

Our LAG-3 immunotherapies are distinctly designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.

Latest press releases.

November 14th 2024

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
November 14th 2024

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting
October 29th 2024

Immutep Quarterly Activities Report Q1 FY25
more

About us.

our science.

Utilizing our LAG-3 expertise, we’re focused on safely delivering on immunotherapy’s promise to drive superior clinical outcomes for patients.

our pipeline.

We have three clinical-stage & two earlier stage candidates, reflecting our unique ability to harness the LAG-3 immune checkpoint in multiple ways to stimulate or suppress the immune system.

investors & media.

We are dedicated to leveraging our technology to develop innovative treatment options for patients and to maximise value to shareholders. Learn more.